Contact
Please use this form to send email to PR contact of this press release:
InterveXion Enrolls First Patient in Phase 2 Study of the Effect of IXT-m200 on Methamphetamine PK and PD
TO:
Misty Stevens
InterveXion Therapeutics
501-554-2377